|
1 Indications And Usage Verzenio ® (abemaciclib) Is Indicated: In Combination With An Aromatase Inhibitor As Initial Endocrine-Based Therapy For The Treatment Of Postmenopausal Women With Hormone Receptor (hr)-Positive, Human Epidermal Growth Factor Receptor 2 (her2)-Negative Advanced Or Metastatic Breast Cancer. In Combination With Fulvestrant For The Treatment Of Women With Hormone Receptor (hr)-Positive, Human Epidermal Growth Factor Receptor 2 (her2)-Negative Advanced Or Metastatic Breast Cancer With Disease Progression Following Endocrine Therapy. As Monotherapy For The Treatment Of Adult Patients With Hr-Positive, Her2-Negative Advanced Or Metastatic Breast Cancer With Disease Progression Following Endocrine Therapy And Prior Chemotherapy In The Metastatic Setting. Verzenio ® Is A Kinase Inhibitor Indicated: In Combination With An Aromatase Inhibitor As Initial Endocrine-Based Therapy For The Treatment Of Postmenopausal Women With Hormone Receptor (hr)-Positive, Human Epidermal Growth Factor Receptor 2 (her2)-Negative Advanced Or Metastatic Breast Cancer. ( 1 ) In Combination With Fulvestrant For The Treatment Of Women With Hormone Receptor (hr)-Positive, Human Epidermal Growth Factor Receptor 2 (her2)-Negative Advanced Or Metastatic Breast Cancer With Disease Progression Following Endocrine Therapy. ( 1 ) As Monotherapy For The Treatment Of Adult Patients With Hr-Positive, Her2-Negative Advanced Or Metastatic Breast Cancer With Disease Progression Following Endocrine Therapy And Prior Chemotherapy In The Metastatic Setting. ( 1 )
|